Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 13 May 2027
Nemolizumab for treating prurigo nodularis [ID6451]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for Prurigo Nodularis [ID6571]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC